Top

Published in:

01-12-2016 | Antimicrobial Development and Drug Resistance (A Pakyz, Section Editor)

Antibiotic Resistance in Pediatric Urinary Tract Infections

Authors: Jeremy S. Stultz, Christopher D. Doern, Emily Godbout

Published in: Current Infectious Disease Reports | Issue 12/2016

Abstract

Urinary tract infections (UTIs) are a common problem in pediatric patients. Resistance to common antibiotic agents appears to be increasing over time, although resistance rates may vary based on geographic region or country. Prior antibiotic exposure is a pertinent risk factor for acquiring resistant organisms during a first UTI and recurrent UTI. Judicious prescribing of antibiotics for common pediatric conditions is needed to prevent additional resistance from occurring. Complex pediatric patients with histories of hospitalizations, prior antibiotic exposure, and recurrent UTIs are also at high risk for acquiring UTIs due to extended spectrum beta-lactamase-producing organisms. Data regarding the impact of in vitro antibiotic susceptibility testing interpretation on UTI treatment outcomes is lacking.

Shaikh N, Morone NE, Bost JE, Farrell MH. Prevalence of urinary tract infection in childhood: a meta-analysis. Pediatr Infect Dis J. 2008;27(4):302–8. doi:10.1097/INF.0b013e31815e4122.CrossRefPubMed

Freedman AL, Urologic Diseases in America Project. Urologic diseases in North America Project: trends in resource utilization for urinary tract infections in children. J Urol. 2005;173(3):949–54.CrossRefPubMed

Edlin RS, Shapiro DJ, Hersh AL, Copp HL. Antibiotic resistance patterns of outpatient pediatric urinary tract infections. J Urol. 2013;190(1):222–7. doi:10.1016/j.juro.2013.01.069.CrossRefPubMedPubMedCentral

Dayan N, Dabbah H, Weissman I, Aga I, Even L, Glikman D. Urinary tract infections caused by community-acquired extended-spectrum beta-lactamase-producing and nonproducing bacteria: a comparative study. J Pediatr. 2013;163(5):1417–21. doi:10.1016/j.jpeds.2013.06.078.CrossRefPubMed

Copp HL, Shapiro DJ, Hersh AL. National ambulatory antibiotic prescribing patterns for pediatric urinary tract infection, 1998–2007. Pediatrics. 2011;127(6):1027–33. doi:10.1542/peds.2010-3465.CrossRefPubMedPubMedCentral

Strohmeier Y, Hodson EM, Willis NS, Webster AC, Craig JC. Antibiotics for acute pyelonephritis in children. Cochrane Database Syst Rev. 2014;7, CD003772. doi:10.1002/14651858.CD003772.pub4.

Subcommittee on Urinary Tract Infection, Steering Committee on Quality Improvement and Management, Roberts KB. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. Pediatrics. 2011;128(3):595–610. doi:10.1542/peds.2011-1330.CrossRef

Clinical and Laboratory Science Institute. Performance standards for antimicrobial susceptibility testing: twenty-fifth informational supplement. 2015;Wayne, PA, USA: Clinical and Laboratory Standards Institute.

European Committee on Antimicrobial Susceptibility Testing. Performance standards for antimicrobial susceptibility testing: twenty-fifth informational supplement. 2015;Version 5.0.

10.

Rose L, Coulter MM, Chan S, Hossain J, Di Pentima MC. Trends of fluoroquinolone-resistant Escherichia coli amongst urinary isolates in children: a 10 year surveillance study. J Med Microbiol. 2015;64(7):778–81. doi:10.1099/jmm.0.000072.CrossRefPubMed

11.

•Bitsori M, Maraki S, Galanakis E. Long-term resistance trends of uropathogens and association with antimicrobial prophylaxis. Pediatr Nephrol. 2014;29(6):1053–8. doi:10.1007/s00467-013-2719-x. This study looked at antimicrobial resistance over a 12-year period in Greece and found significant increases in isolation of resistant organisms over the study period in pediatric patients. The study also found that prior antibiotic exposure was an independent risk factor for acquiring a UTI with a resistant organism. CrossRefPubMed

12.

Mohammad-Jafari H, Saffar MJ, Nemate I, Saffar H, Khalilian AR. Increasing antibiotic resistance among uropathogens isolated during years 2006–2009: impact on the empirical management. Int Braz J Urol. 2012;38(1):25–32.CrossRefPubMed

13.

••Bryce A, Hay AD, Lane IF, Thornton HV, Wootton M, Costelloe C. Global prevalence of antibiotic resistance in paediatric urinary tract infections caused by Escherichia coli and association with routine use of antibiotics in primary care: systematic review and meta-analysis. BMJ. 2016;352:i939. doi:10.1136/bmj.i939. This study was a meta-analysis of global E. coli UTI antimicrobial resistance in pediatric patients. It found significant differences between countries, with higher resistance rates in countries with over the counter antibiotics. Also, the meta-analysis found a significant association with prior antibiotic exposure up to 6 months and increased antibiotic resistance. CrossRefPubMedPubMedCentral

14.

Boggan JC, Navar-Boggan AM, Jhaveri R. Pediatric-specific antimicrobial susceptibility data and empiric antibiotic selection. Pediatrics. 2012;130(3):e615–22. doi:10.1542/peds.2012-0563.CrossRefPubMed

15.

McGregor JC, Quach Y, Bearden DT, Smith DH, Sharp SE, Guzman-Cottrill JA. Variation in antibiotic susceptibility of uropathogens by age among ambulatory pediatric patients. J Pediatr Nurs. 2014;29(2):152–7. doi:10.1016/j.pedn.2013.09.001.CrossRefPubMed

16.

Keren R, Shaikh N, Pohl H, et al. Risk factors for recurrent urinary tract infection and renal scarring. Pediatrics. 2015;136(1):e13–21. doi:10.1542/peds.2015-0409.CrossRefPubMedPubMedCentral

17.

Shaikh N, Ewing AL, Bhatnagar S, Hoberman A. Risk of renal scarring in children with a first urinary tract infection: a systematic review. Pediatrics. 2010;126(6):1084–91. doi:10.1542/peds.2010-0685.CrossRefPubMed

18.

Conway PH, Cnaan A, Zaoutis T, Henry BV, Grundmeier RW, Keren R. Recurrent urinary tract infections in children: risk factors and association with prophylactic antimicrobials. JAMA. 2007;298(2):179–86.CrossRefPubMed

19.

Mantadakis E, Tsalkidis A, Panopoulou M, et al. Antimicrobial susceptibility of pediatric uropathogens in Thrace, Greece. Int Urol Nephrol. 2011;43(2):549–55. doi:10.1007/s11255-010-9768-x.CrossRefPubMed

20.

Jakovljevic E, Ilic K, Jelesic Z, Konstantinidis G. A one-year prospective study on the antibiotic resistance of E. coli strains isolated in urinary specimens of children hospitalized at the University Pediatric Medical Center in Novi Sad, Serbia. Infection. 2013;41(6):1111–9. doi:10.1007/s15010-013-0493-0.CrossRefPubMed

21.

Rezaee MA, Abdinia B. Etiology and antimicrobial susceptibility pattern of pathogenic bacteria in children subjected to UTI: a referral hospital-based study in northwest of Iran. Medicine (Baltimore). 2015;94(39), e1606. doi:10.1097/MD.0000000000001606.CrossRef

22.

Paschke AA, Zaoutis T, Conway PH, Xie D, Keren R. Previous antimicrobial exposure is associated with drug-resistant urinary tract infections in children. Pediatrics. 2010;125(4):664–72. doi:10.1542/peds.2009-1527.CrossRefPubMed

23.

Caracciolo A, Bettinelli A, Bonato C, et al. Antimicrobial resistance among Escherichia coli that cause childhood community-acquired urinary tract infections in northern Italy. Ital J Pediatr. 2011;37:3. doi:10.1186/1824-7288-37-3.CrossRefPubMedPubMedCentral

24.

Sakran W, Smolkin V, Odetalla A, Halevy R, Koren A. Community-acquired urinary tract infection in hospitalized children: etiology and antimicrobial resistance. A comparison between first episode and recurrent infection. Clin Pediatr (Phila). 2015;54(5):479–483. doi: 10.1177/0009922814555974.

25.

••RIVUR Trial Investigators, Hoberman A, Greenfield SP, et al. Antimicrobial prophylaxis for children with vesicoureteral reflux. N Engl J Med. 2014;370(25):2367–76. doi:10.1056/NEJMoa1401811. This was the largest and likely highest quality prospective study regarding the use of prophylactic antibiotics to prevent UTI for pediatric patients with vesicoureteral reflux. Important to this review, patients on prophylactic antibiotics had higher rates of UTIs due to a resistant organism. CrossRef

26.

Ashkenazi-Hoffnung L, Melamed N, Ben-Haroush A, Livni G, Amir J, Bilavsky E. The association of intrapartum antibiotic exposure with the incidence and antibiotic resistance of infantile late-onset serious bacterial infections. Clin Pediatr (Phila). 2011;50(9):827–33. doi:10.1177/0009922811406260.CrossRef

27.

Nelson CP, Hoberman A, Shaikh N, et al. Antimicrobial resistance and urinary tract infection recurrence. Pediatrics. 2016;137(4). doi: 10.1542/peds.2015-2490.

28.

•Fan NC, Chen HH, Chen CL, et al. Rise of community-onset urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli in children. J Microbiol Immunol Infect. 2014;47(5):399–405. doi:10.1016/j.jmii.2013.05.006. This was a study looking at ESBL production over a 5-year period in pediatric urinary isolates. Mild increases in resistance over time were noted, and risk factors for ESBL UTI pathogens were identified including recent hospitalizations, neurologic diseases, and recent antibiotic exposure. CrossRefPubMed

29.

Kizilca O, Siraneci R, Yilmaz A, et al. Risk factors for community-acquired urinary tract infection caused by ESBL-producing bacteria in children. Pediatr Int. 2012;54(6):858–62. doi:10.1111/j.1442-200X.2012.03709.x.CrossRefPubMed

30.

Tratselas A, Iosifidis E, Ioannidou M, et al. Outcome of urinary tract infections caused by extended spectrum beta-lactamase-producing Enterobacteriaceae in children. Pediatr Infect Dis J. 2011;30(8):707–10. doi:10.1097/INF.0b013e31820d7ec4.CrossRefPubMed

31.

Degnan LA, Milstone AM, Diener-West M, Lee CK. Extended-spectrum beta-lactamase bacteria from urine isolates in children. J Pediatr Pharmacol Ther. 2015;20(5):373–7. doi:10.5863/1551-6776-20.5.373.PubMedPubMedCentral

32.

Navidinia M, Peerayeh SN, Fallah F, Bakhshi B, Sajadinia RS. Phylogenetic grouping and pathotypic comparison of urine and fecal Escherichia coli isolates from children with urinary tract infection. Braz J Microbiol. 2014;45(2):509–14.CrossRefPubMedPubMedCentral

33.

Lieberthal AS, Carroll AE, Chonmaitree T, et al. The diagnosis and management of acute otitis media. Pediatrics. 2013;131(3):e964–99. doi:10.1542/peds.2012-3488.CrossRefPubMed

34.

Wald ER, Applegate KE, Bordley C, et al. Clinical practice guideline for the diagnosis and management of acute bacterial sinusitis in children aged 1 to 18 years. Pediatrics. 2013;132(1):e262–80.CrossRefPubMed

35.

Ralston SL, Lieberthal AS, Meissner HC, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014;134(5):e1474–502. doi:10.1542/peds.2014-2742.CrossRefPubMed

36.

Chen PC, Chang LY, Lu CY, et al. Drug susceptibility and treatment response of common urinary tract infection pathogens in children. J Microbiol Immunol Infect. 2014;47(6):478–83. doi:10.1016/j.jmii.2013.07.011.CrossRefPubMed

37.

Bactrim(R) [package insert]. Philadelphia, PA; Mutual Pharmaceutical Company, INC:2013.

38.

Ancef (R) [package insert]. Research Triangle Park, NC; GlaxoSmithKline:2004.

39.

Lee B, Kang SY, Kang HM, et al. Outcome of antimicrobial therapy of pediatric urinary tract infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae. Infect Chemother. 2013;45(4):415–21. doi:10.3947/ic.2013.45.4.415.CrossRefPubMedPubMedCentral

40.

Han SB, Lee SC, Lee SY, Jeong DC, Kang JH. Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae. BMC Infect Dis. 2015;15:414-015-1153-z. doi: 10.1186/s12879-015-1153-z.

41.

Raz R, Chazan B, Kennes Y, et al. Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin Infect Dis. 2002;34(9):1165–9.CrossRefPubMed

42.

Talan DA, Stamm WE, Hooton TM, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial. JAMA. 2000;283(12):1583–90.CrossRefPubMed

Title: Antibiotic Resistance in Pediatric Urinary Tract Infections
Authors: Jeremy S. Stultz
Christopher D. Doern
Emily Godbout
Publication date: 01-12-2016
Publisher: Springer US
Published in: Current Infectious Disease Reports / Issue 12/2016
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI: https://doi.org/10.1007/s11908-016-0555-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2016

Azole Resistance in Candida glabrata

Resistance to Non-glycopeptide Agents in Serious Staphylococcus aureus Infections

Emerging Issues and Treatment Strategies in Carbapenem-Resistant Enterobacteriaceae (CRE)

Lung Ultrasound Will Soon Replace Chest Radiography in the Diagnosis of Acute Community-Acquired Pneumonia

Thoughts Around the Zika Virus Crisis

Hepatic and Intra-abdominal Tuberculosis: 2016 Update

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials